In this study,  we utilized real-world comprehensive genomic and immune profiling (CGIP) data derived from testing many patients with NSCLC (>8,000) during their standard care to look for differences in genomic alterations and immune activity in younger versus older patient tumors. We found important differences in younger patient tumors including higher frequency of genomic alterations in key NSCLC driver genes and less immune activity overall, especially when looking at male patient tumors. Taken together, our results show the value of CGIP for informing clinical treatment of younger patients with NSCLC and provides support for broader coverage of CGIP for younger patients.

• Download

Published in: Frontiers in Immunology